Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
Status:
RECRUITING
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced non-squamous non-small cell lung cancer following resistance to EGFR-TKI.
Phase:
PHASE2
Details
Lead Sponsor:
Guangzhou University of Traditional Chinese Medicine